RxDoctor Payments Data

Riley Henderson, APRN

Family · Sparks, NVNPI 1811777089

Payments from drug & device makers

$2,424in general payments, 2019–2025

Across 125 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$127
  • Galderma Laboratories, L.p.$114
  • Merck$58
  • GSK$35
  • Pfizer$22
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$2,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie112$2,051
Amgen5$127
Galderma Laboratories, L.p.1$114
Merck3$58
GSK2$35
Pfizer1$22
Novo Nordisk1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,424 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$358
Medicare patients
16
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin39$36,568
TrulicityDulaglutide16$23,777
JanuviaSitagliptin Phosphate21$19,074
MounjaroTirzepatide15$15,958
TradjentaLinagliptin11$11,599
EliquisApixaban12$9,178
SynjardyEmpagliflozin/Metformin Hcl12$8,651
MyrbetriqMirabegron13$7,187
SymbicortBudesonide/Formoterol Fumarate11$4,681
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,283
Albuterol Sulfate HfaAlbuterol Sulfate37$1,428
Gabapentin23$616
Atorvastatin Calcium114$519
Levothyroxine Sodium44$411
Omeprazole51$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$58$19,07421 claims
PfizerEliquis$22$9,17812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,501 family providers in Nevada.

Other family in Sparks

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →